HEDIS increasingly relies on clinical data and organizations must adapt their quality reporting operations to achieve their performance targets. Remaining successful each year requires a strategy that anticipates a future with FHIR, but executes on the real-world data existing today. Hear from NCQA’s data quality experts on current trends in the volumes, types and standards adopted for current supplemental data sources. They’ll describe the continuum of data used for HEDIS that will allow attendees to assess if they’re leading or lagging in their data strategy. Rare information will be shared on the variety of techniques being used for HEDIS supplemental data collection (e.g., manual abstraction, electronic queries), what types of transformation are occurring (e.g., code mapping, data model conformance) and how organizations are approaching internal validation (e.g., primary source verification, referential integrity logs). The panelists will speak to the core challenge many organizations face: scaling up clinical data availability while maintaining high confidence in the data quality. Panelists will share examples of how leading organizations strike this balance, and some pitfalls that emerge when data volume is prioritized over data integrity. Whether you're exploring opportunities to leverage data from EHRs, registries, data aggregators, internal case management or member engagement programs, this session will provide considerations as you execute on that plan. The panelists are fluent in HEDIS and will close out by connecting this back to the latest changes in HEDIS Volume 2. They’ll give examples of how HEDIS measure set transitions cascade down to an organization’s supplemental data operations. Hear observations on how measures with new in-kind data elements—such as the Glucose Management Indicator (GMI) and BIRADS categories– appear (or don’t appear) in today’s data sources. They’ll describe how shifts from traditional hybrid reporting to Electronic Clinical Data System are reshaping data collection capabilities and validation needs. Throughout the session, the panel insights will help organizations: • Benchmark their current inventory of clinical data against national trends. • Learn of risks in transformation and internal validation that could prevent the contribution of a source towards HEDIS. Note: if this panel is selected, it will be moderated by NCQA staff and two HEDIS Compliance Audit Firm executives will be selected to join.